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Pathological mutations in the mitochondrial DNA (mtDNA) produce a diverse range of tissue-
specific diseases and the proportion of mutant mitochondrial DNA can increase or decrease 
with time via segregation, dependent on the cell or tissue type. Previously we found that 
adenocarcinoma (A549.B2) cells favored wild-type (WT) mtDNA, whereas 
rhabdomyosarcoma (RD.Myo) cells favored mutant (m3243G) mtDNA. Mitochondrial quality 
control (mtQC) can purge the cells of dysfunctional mitochondria via mitochondrial dynamics 
and mitophagy and appears to offer the perfect solution to the human diseases caused by 
mutant mtDNA. In A549.B2 and RD.Myo cybrids, with various mutant mtDNA levels, mtQC 
was explored together with macroautophagy/autophagy and bioenergetic profile. The 2 types 
of tumor-derived cell lines differed in bioenergetic profile and mitophagy, but not in 
autophagy. A549.B2 cybrids displayed upregulation of mitophagy, increased mtDNA removal, 
mitochondrial fragmentation and mitochondrial depolarization on incubation with 
oligomycin, parameters that correlated with mutant load. Conversely, heteroplasmic RD.Myo 
lines had lower mitophagic markers that negatively correlated with mutant load, combined 
with a fully polarized and highly fused mitochondrial network. These findings indicate that 
pathological mutant mitochondrial DNA can modulate mitochondrial dynamics and 
mitophagy in a cell-type dependent manner and thereby offer an explanation for the 





 Mitochondria are dynamic organelles that continually undergo fusion and fission 
events in order to share their content and optimize their function.1 Mitochondria generate 
much of the cell’s ATP, house essential biosynthetic and metabolic pathways, participate in 
calcium and redox homeostasis and are key regulators of apoptosis. It is crucial for cell 
survival to maintain an efficient mitochondrial population through the elimination of 
dysfunctional mitochondria; hence there are multiple mechanisms acting at the molecular and 
organelle level to achieve mitochondrial quality control (mtQC).2, 3 At the organelle level, 
when mitochondria become dysfunctional they form discrete organelles that are unable to 
fuse with the mitochondrial network4 thereby facilitating their removal and destruction via 
autophagy, a process named mitophagy. Mitophagy is mainly mediated by 2 pathways, the 
PINK1 (PTEN induced putative kinase 1 )- PARK2 (parkin RBR E3 ubiquitin protein ligase ) and 
BNIP3 (BCL2 interacting protein 3)- BNIP3L (BCL2 interacting protein 3 like ) systems.5 In the 
PINK1-PARK2 pathway mitophagy is usually triggered by an accumulation of PINK1 on 
mitochondria. PINK1 is imported and constitutively degraded in healthy mitochondria but 
after mitochondrial injury, PINK1 is stabilized and accumulates in the outer membrane, 
where it binds and recruits PARK2, an E3 ubiquitin ligase.6 PARK2 ubiquitinates various 
mitochondrial proteins of the outer mitochondrial membrane, including the mitochondrial  
fusion proteins MFN1 (mitofusin1) and MFN2. The subsequent proteasomal-dependent 
degradation of mitofusins prevents fusion of the PARK2-positive mitochondria.7 Finally, the 
ubiquitinated mitochondria are recognized by the ubiquitin-binding autophagic receptors, 
such as SQSTM1/p62 (sequestosome 1), NBR1, and OPTN (optineurin), that, by interacting 
with both poly-ubiquitin chains and LC3 (microtubule associated protein 1 light chain 3 beta), 
recruit the LC3-positive phagophore (the autophagosome precursor) on the surface of the 
dysfunctional fragmented mitochondria.8-10 The BNIP3-BNIP3L system works by directly 
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binding LC3 and therefore by docking the nascent phagophore on the mitochondria that 
accumulate BNIP3 or BNIP3L.5 Therefore these mechanisms of selective mtQC involve not 
only mitophagy but also the synchronous regulation of the mitochondrial shaping machinery. 
3-11  
 The human mitochondrial genome (mtDNA) encodes 13 polypeptides, all essential 
subunits of the oxidative phosphorylation system (OXPHOS). Mutations in the mtDNA are 
responsible for a wide range of diseases.12 The most common point mutation is an adenine to 
guanine transition at nucleotide position 3243 (m3243G), in the MT-TL1 gene 
(mitochondrially encoded tRNA leucine 1 (UUA/G)), responsible for several clinical phenotypes, 
including syndromes characterized by Mitochondrial Encephalomyopathy, Lactic Acidosis, 
and Stroke-like episodes (MELAS), cardiomyopathy, and Maternally Inherited Diabetes and 
Deafness (MIDD).13,14 Human cells have thousands of copies of mtDNA and individuals with 
pathogenetic mtDNA mutations often carry a mixture of mutated and wild-type (WT) mtDNAs 
in their cells, a situation referred to as heteroplasmy. A specific threshold level of mutant 
mtDNA must be exceeded to cause a respiratory chain defect in the cells.15, 16 There is often a 
marked variation in the level of mutant mtDNA among tissues that is thought to be 
responsible for the diverse clinical phenotypes associated with the pathological mtDNA 
mutations.17 Therefore, the segregation to high level of mutant mtDNA is the major factor in 
determining the pattern and severity of the disease phenotype. Multiple studies have revealed 
cell and tissue specific segregation of mutant mtDNA.17-24 Generally, in the same individual 
mutant mtDNA molecules accumulate in tissues, such as muscle, brain, heart; the opposite of 
what occurs in blood and lung where mutant load is lower.17-20 In line with in vivo results, we 
found that mutated mtDNA was accumulated in RD.Myo cybrids,21, 22 while WT mtDNA was 
selected in A549.B2 cybrids.23, 24 A better understanding of the molecular mechanisms 
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underpinning the selection of mutant or wild-type mtDNA would provide new therapeutic 
approaches for mitochondrial diseases that are currently largely incurable.25 
 Because mtQC offers a means of degrading mitochondria whose energy-producing 
capacity is compromised,4, 5 it might account for the ability of A549.B2 cells to select wild-type 
mtDNA in preference to mutant m3243G. Therefore, we evaluated autophagy, mitophagy and 
mitochondrial dynamics in muscle and lung-derived tumor cell lines harboring different levels 
of m3243G, and related the findings to cellular energy status. 
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RESULTS 
 RD.Myo cells have a higher bioenergetic profile than A549.B2 cells 
 Considering the interplay of cellular bioenergetics and mtQC,26, 27 oxidative 
phosphorylation and glycolytic parameters were analyzed in A549.B2 and RD.Myo cybrids, 
carrying different, but stable, proportions of mutant (m3243G) and wild-type mtDNA (Fig. 
S1A and B). Mitochondrial ATP synthesis rates were similar in both WT and heteroplasmic 
A549.B2 and RD.Myo cybrids, when expressed relative to CS (citrate synthase), a widely used 
marker of mitochondrial mass (Fig. 1A).28 However, the A549.B2 cybrids had only around one 
third of the citrate synthase activity of the RD.Myo cybrids (Fig. 1B), suggesting the capacity 
of their mitochondria to produce ATP was low, and this was reflected in the steady-state level 
of ATP (Fig. 1C). Despite the RD.Myo cybrids had greater mitochondrial ATP producing 
capacity, they were less dependent on their mitochondria than the A549.B2 cybrids based on 
a comparison of the pair of cybrids with 100% m3243G (Fig. 1A,C). Mutant load had no 
impact on ATP level in the RD.Myo cybrids, whereas the A549.B2 cybrid with 100% of the 
m3243G mutation had significantly less ATP than sister cybrids with lower mutant loads (Fig. 
1C). Hence, the high level of ATP in the 100% m3243G RD.Myo cybrids must derive from 
glycolysis, and this was corroborated by the much higher levels of HK2 (hexokinase 2) (an 
index of glycolytic metabolism29) in RD.Myo cybrids compared to A549.B2 cybrids (Fig. 1D to 
G). These results are concordant with the low activity of glycolytic enzymes of A549 cells 
compared with C2C12 muscle-derived cell line reported by Guha,30 and the small glycolytic 
contribution (~5%) to the total ATP produced by A549 cells.31 The state 3 and 4 
mitochondrial membrane potential and their ratio paralleled the mitochondrial ATP synthesis 
activity (relative to CS, Fig. 1A), with only the homoplasmic mutant cybrids displaying a 
significantly lower membrane potential than the controls (Fig. 1H,I). 
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 In summary in our culture conditions, WT and heteroplasmic A549.B2 and RD.Myo 
cybrids had similar OXPHOS efficiency but a different bioenergetic profile. In line with 
previous in vitro 30-32 and in vivo results,33 A549.B2 cells displayed low glycolytic capacity and 
reduced mitochondrial mass, on the contrary, RD.Myo cybrids showed high glycolytic and 
oxidative phosphorylation capacity.  
 
 Autophagy flux is not impaired in RD.Myo cybrids  
 Autophagy is an essential degradation pathway that clears the cell of redundant or 
damaged proteins and organelles.34,35 Moreover, the autophagy-lysosome system is also 
important for cell survival during stress conditions, such as in the absence of nutrients.35 If the 
unusual ability of A549.B2 cells to eliminate mutant mtDNA23, 24 is underpinned by mitophagy, 
then A549.B2 cells might display increased autophagic flux, compared to RD.Myo cells. When 
we analyzed LC3-II and SQSTM1 amounts as well as the autophagic flux, i.e. the increase of 
these markers after chloroquine (CQ) treatment (Fig. 2A to D),36 we found that A549.B2 cells 
without mutant mtDNA display greater autophagic flux than the equivalent RD.Myo cells. 
However, the situation is reversed in heteroplasmic cybrids (Fig. 2A). These data suggest that 
pathological mtDNA mutations can influence the process of autophagy but argue against 
changes in overall autophagy flux, being the explanation for the ability of A549.B2, and not 
RD.Myo, cybrids to purge their cells of mutant mtDNA. 
 
 Mitophagy flux is higher in A549.B2 than RD.Myo cybrids  
 Mitophagy is the specific degradation of mitochondria, or components thereof, by 
lysosomes via an autophagic process, and it has a mechanistically separate induction and 
regulation from total autophagy.5-6 PINK1, PARK2 and BNIP3 are the major players in the 
mitophagy process, that allow the recruitment of the phagophore to the damaged 
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mitochondria.5,6,37-38 To understand if mitophagy flux differed between A549.B2 and RD.Myo 
cells, with and without mutant mtDNA, we employed the following biochemical, molecular 
and imaging assays. 
 First, we carried out a biochemical analysis. Mitophagy was estimated by monitoring 
the recruitment of LC3-II, SQSTM1/p62, PINK1, PARK2, and BNIP3 on isolated mitochondria. 
The enrichment of these markers after CQ treatment was evaluated to provide an index of 
mitophagy flux36 (Fig. 2E to G; Fig. 3A to C,  
I to M; Fig. S2).  
 Unlike general autophagy, mitophagy diverged in A549.B2 and RD.Myo cells. In WT 
and heteroplasmic A549.B2 cybrids with mitochondrial LC3-II (mtLC3-II) and SQSTM1/p62 
(mtSQSTM1/p62) increased after CQ treatment 3.3-3.8 and 5.7 times while minor changes 
occurred in RD.Myo (Fig. 2E, G; Fig. S2). In A549.B2 cybrids these increases showed a 
significant positive correlation with m3243G mutant mtDNA accumulation (Fig. 2H, M; Fig. 
S3A and B). Conversely, in RD.Myo cells the amount of mtLC3-II negatively correlated with 
mutant load (Fig. 2L), while mtSQSTM1 did not display any correlation with m3243G (Fig. 
2N). Since LC3-II is a key mediator of autophagy these results suggested A549.B2 cybrids 
utilized mitophagy as a mitochondrial degradation pathway significantly more than RD.Myo 
cybrids.  
 Consistent with mtLC3 and mtSQSTM1 data, the mitochondrial recruitment of PINK1 
(mtPINK1), PARK2 (mtPARK2) and BNIP3 (mtBNIP3) was significantly enhanced in A549.B2 
but not in RD.Myo cell lines (Fig. 3; Fig. S2). Indeed, the turnover rate of mtPINK1 was 2.4 to 
3.7 times greater in WT and heteroplasmic A549.B2 than in RD.Myo cybrids (Fig. 3A, 3I), and 
there was no detectable signal of PARK2 (at around 50 kDa) in mitochondria of RD.Myo 
cybrids (Fig. 3L), probably for an insufficient PARK2 expression level (Fig. 3P) and 
consequent mitochondrial recruitment. Moreover, mtPINK1, mtPARK2, mtBNIP3 levels and 
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flux positively correlated with the increase of m3243G mutated mtDNA in A549.B2 cells (Fig. 
3D,F,G; Fig. S3C to E) whereas an inverse trend for PINK1 (Fig. 3E) (P< 0,001) or no 
correlation (Fig. 3H) for BNIP3 was detected in RD.Myo cells. The opposite behavior of PINK1 
in the 2 cell lines might reflect the fact that A549.B2 and RD.Myo cells express different 
species (Fig. 3I),39 confirmed by an siRNA approach, done in parallel with PARK2 
downregulation (Fig S4). 
 We also tested the CQ mediated accumulation of the recently reported mitophagic 
receptors , FUNDC1 (FUN14 domain containing 1)40 and BCL2L13 (BCL2 like 13)41 on isolated 
mitochondria of A549.B2 cells. CQ did not change the mitochondrial protein level of FUNDC1, 
a receptor for hypoxia-induced mitophagy40 (Fig. S5A and B); on the contrary, CQ resulted in 
a significant 3-fold increase of mitochondrial BCL2L13 amount in both WT and heteroplasmic 
A549.B2 cells (Fig. S5A, S5C). In addition, mitochondrial BCL2L13 was 3-4 fold augmented in 
heteroplasmic mutant vs WT mitochondria.  These results suggested that BCL2L13, but not 
FUNDC1, played a role in the active mitophagic flux in A549.B2 cells, probably both inducing 
fragmentation and/or cooperating with the PINK1-PARK2 system.41 
 Next we carried out a molecular analysis. To establish whether the difference of 
mitophagy between A549.B2 and RD.Myo cells might be ascribed to a transcriptionally-
dependent regulation of these factors, we evaluated the expression of PINK1, PARK2 and 
BNIP3 by quantitative RT-PCR. To validate this comparison, the transcript level of the 2 
housekeeping genes was estimated in a fixed number (107) of A549.B2 and RD.Myo cells. Both 
RPLP0 (ribosomal protein lateral stalk subunit P0) and B2M (beta-2-microglobulin), the 2 
housekeeping genes, were similar in the 2 cell types and were unaffected by m3243G mutant 
load (Fig. 3N). In WT and heteroplasmic mutant RD.Myo cells, the transcript level of PINK1 
was significantly lower than in A549.B2 cybrids (Fig. 3O). Similarly, PARK2 expression was 
also decreased in RD.Myo cells (Fig. 3P), while PINK1, PARK2 and BNIP3 mRNAs were 
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significantly increased in heteroplasmic vs 0% A549.B2 cells (Fig. 3O to Q). Thus, A549.B2 
but not RD.Myo cells, showed transcriptional induction of PINK1, PARK2 and BNIP3 in 
response to mutant mtDNA.  
 Subsequently, we examined mtDNA removal. To test mitochondrial disposal by 
mitophagy, mtDNA removal was determined by quantification of mtDNA copy number in WT 
and heteroplasmic mutant A549.B2 and RD.Myo cells untreated and treated with ethidum 
bromide (EtBr) (50 ng/ml) for 22 h with and without CQ, as described42 (Fig. 4A and B). EtBr, 
blocking the mtDNA synthesis,43-45 reduced the mtDNA copy number at 60% and 75% in WT 
and heteroplasmic A549.B2 cells respectively, as compared to the untreated cells. The 
concomitant addition of CQ increased significantly mtDNA amount of 21% in WT A549.B2 
(EtBr+CQ vs EtBr P<0.05) and of 31% in heteroplasmic A549.B2 (EtBr+CQ vs EtBr P<0.001), 
showing the percentage of mtDNA degradation consequent to mitophagy (Fig. 4A). Similarly, 
in both WT and heteroplasmic RD.Myo, EtBr reduced the mtDNA amount at 58 to 60%, CQ 
treatment produced a slight and not significant increase of 14% and 3% in WT and 
heteroplasmic cells, respectively, indicating a reduced removal of mtDNA in RD.Myo cells (Fig. 
4B). The differences between mtDNA copy number of control (untreated cells) and CQ + EtBr 
treated cells were proportional to the growth rate, expressed as duplication time (Fig. S1C) 
and represented the portion of mtDNA synthesized to fill up the dividing cells. 
 Finally, we used a morphological analysis. The inference, from the LC3-II (Fig. 2), 
PINK1-PARK2 and BNIP3 abundances and turnover (Fig. 3) and mitophagic mtDNA 
degradation (Fig. 4A and B), that RD.Myo cells largely eschew mitophagy compared to 
A549.B2 cells, was further corroborated by confocal microscopy analysis of cells transfected 
with GFP-LC3B and red fluorescent protein targeted to mitochondria (mtRFP). The LC3-
positive puncta that colocalized with mitochondria were quantified and expressed as 
puncta/cell (Fig. 4C to E), in absence of GFP-LC3 aggregates, as tested in detergent-soluble 
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fraction of GFP-LC3B transfected cells immunoblotted for ubiquitin and LC3 (Fig. S6C). In line 
with the above data, also the morphological analysis showed that mitophagy was active in 
A549.B2 but not in RD.Myo cells. In fact, CQ treatment enhanced 3.3-4.6 fold the double 
positive vesicles in A549.B2 cybrids, but only 1.3 to 1.6 fold in RD.Myo cybrids (Fig. 4E). 
Moreover, the heteroplasmic A549.B2 cells carrying the m3243G mutation increased by 50% 
the mitophagic flux when compared to 0% A549.B2 cells (4.6 vs 3.3; Fig. 4C and 4E), in 
accordance with the biochemical data (Fig. 2E, G). Consistently, the high mitophagic flux in 
A549.B2 cells was confirmed by colocalization of endogenous LC3 puncta with 
immunostained mitochondria (by using anti-LC3B and anti- ATP5J antibodies) (Fig. S6A and 
B).  
 These findings indicated a greater mitophagic capacity and flux in A549.B2 than 
RD.Myo cells. Moreover, m3243G enhanced mitophagy in A549.B2 but not in RD.Myo cybrids. 
These differences did not reflect a deficiency of the lysosomal degradation pathway in RD.Myo 
cells, as autophagy was active in heteroplasmic RD.Myo cells (Fig. 2A and B, D).  
  
 A fragmented mitochondrial network is permissive for mitophagy in A549.B2 
cybrids  
 Modulation of mitochondrial shape plays a key role during mitophagy.3, 4 
Mitochondrial fragmentation is necessary for the removal of damaged organelles, while 
mitochondrial fusion can complement damaged or dysfunctional units and possibly recover 
their activity, thereby maintaining metabolic efficiency.1, 46 Hence, one means by which 
RD.Myo cells might avoid or prevent mitophagy would be to organize their mitochondria in an 
interconnected reticular network. Conversely, A549.B2 cells might have a more fragmented 
mitochondrial population to enhance mitophagy. Therefore, we assessed whether 
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mitochondrial morphology was consistent with the differences in mitophagy of A549.B2 and 
RD.Myo cells.  
 Labeling of the mitochondria of A549.B2 and RD.Myo cybrids with mt-RFP indicated 
that the A549.B2 cells displayed many fragmented mitochondria, whereas RD.Myo cells 
showed tubular interconnected mitochondria (Fig. 4F and G) (RD.Myo vs A549.B2 P<0.001). 
The difference was accentuated by the presence of m.3243G mutant mtDNA, with 
heteroplasmic A549.B2 cybrids having the most fragmented mitochondria, whereas elongated 
mitochondria were most extensive in RD.Myo cybrids with mutant mtDNA (Fig. 4G). 
 Three mammalian proteins are required for mitochondrial fusion.47 Mitofusins (MFN1, 
MFN2) are important for outer membrane fusion while OPA1 is involved in inner membrane 
fusion.48, 49 Mitochondrial fission is mediated by  DNM1L  (dynamin 1 like ), which is recruited 
to mitochondria via the receptor proteins MFF (mitochondrial fission factor), FIS1 (fission, 
mitochondrial 1), MIEF1 (mitochondrial elongation factor 1) and MIEF2 (mitochondrial 
elongation factor 2 ).50, 51 Besides the receptor recruitment, DNM1L needs also to be activated 
by a PPP3/calcineurin-dependent dephosphorylation.52 Consistent with the mitochondrial 
morphology, the DNM1L was significantly more enriched in the mitochondrial fraction of 
A549.B2 cells than those of the equivalent RD.Myo cells (Fig. 5A,C) (0% A549.B2 vs RD.Myo 
P<0.05; 35 to 80% A549.B2 vs 70 to 80% RD.Myo p<0.005). Consistently, the phospho- 
DNM1L:DNM1L ratio was reduced in the cytosol of A549.B2 compared to RD.Myo (Fig. 
5B,D)(0% and 35 to 80% A549.B2 vs 0% and 70 to 80% RD.Myo P<0.005), but was 
significantly increased in cytosol of heteroplamic A549.B2 vs 0% A549.B2 cells (P< 0.01). 
Conversely, the steady state level of the fusion proteins, MFN1, MFN2 and OPA1, were 
significantly higher in isolated mitochondria of RD.Myo cells than those of A549.B2 cybrids 
(Fig. 5E to H). Thus, the fission and fusion machinery of the 2 cell lines predicted fragmented 
mitochondria in A549.B2 cybrids and an extensive reticular network in RD.Myo cells. 
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 In summary A549.B2 cells had discrete mitochondria that were susceptible to 
mitophagy whenever dysfunctional, and they expressed sufficient PINK1 and PARK2 to 
execute mitophagy. Conversely, RD.Myo cells, that had a much lower capacity for mitophagy, 
maintained their mitochondria in a form that was resistant to mQC process. 
 
 Dysfunctional mitochondria are more evident in A549.B2 than in RD.Myo cybrids  
 Since the PINK1-PARK2 system is sensitive to mitochondrial membrane potential 
(Δψm),53, 54 we inferred a different pattern of mitochondrial depolarization in A549.B2 and 
RD.Myo cells. To verify this, we investigated Δψm by flow cytometry of TMRM 
(tetramethylrhodamine methyl ester), a fluorescent probe that accumulates in polarized 
mitochondria and is released when Δψm decreases.55, 56 Since dysfunctional-depolarized 
mitochondria can be masked by the ATP synthase operating in reverse mode, such that Δψm is 
maintained by consuming ATP, we treated the cells with oligomycin, an inhibitor of 
mitochondrial ATP synthase.57, 58 
 Under standard growth conditions depolarized mitochondria accounted for 6% of the 
total in the RD.Myo and 9% in A549.B2 cybrids, with no mutant mtDNA (Fig. 6A, 6B). In 
presence of m3243G mutant mtDNA, mitochondria of RD.Myo cells had a similar Δψm; 
mitochondrial depolarization was obtained only after addition of the protonophore FCCP 
(carbonylcyanide-p-trifluoromethoxyphenyl hydrazone) (Fig. 6B). In A549.B2 cybrids 
m3243G mutated mtDNA induced a 2 fold higher depolarization (Fig. 6A) than in RD.Myo 
cells. Comparing the 2 sets of cybrids, the presence of m.3243G mtDNA was associated with 
significantly higher number of depolarized mitochondria in A549.B2 but not RD.Myo cell lines 
(Fig. 6C).  Blocking autophagy by CQ treatment increased the levels of depolarized 
mitochondria in A549.B2, but not in RD.Myo, cells (Fig. 6D; Fig. S7), thereby, providing strong 
additional evidence that the mitophagy pathway is repressed in RD.Myo cells.  
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 In summary, dysfunctional mitochondria were much more evident in heteroplasmic 
A549.B2 than RD.Myo cells, and mitophagy efficiently removed them to a much greater extent 
in A549.B2 than in RD.Myo cells.   
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DISCUSSION 
 The main findings of the present study indicate that general autophagy and mitophagy 
are dissociated and that regulation of mtQC (i.e.: mitochondrial dynamics and mitophagy) in 
response to m3243G mutant load is cell-type specific.   
 Our original idea was to find higher autophagy in A549.B2 than RD.Myo cells that 
would preferentially remove the mutated mtDNA.21-24 However, there was no significant 
difference of autophagy flux between heteroplasmic A549.B2 and RD.Myo cells and actually 
we observed the opposite of what expected. In fact, autophagy flux was slightly higher in 
RD.Myo than in A549.B2 during accumulation of mutated mtDNA.  
 Differently from general autophagy, the specific elimination of dysfunctional 
mitochondria by mitophagy differs completely between the 2 cell types. In fact, A549.B2 cells 
show higher mitophagy and mitophagic mtDNA removal (Fig. 4A and B), when compared to 
RD.Myo cells. Molecular, biochemical and morphological analyses identified the involvement 
of PINK1-PARK2 and BNIP3 systems in the selective mitochondrial removal (Figs. 2 to 4). 
Furthermore, consistent with mitophagy data, morphological and biochemical analyses 
revealed a different organization of mitochondrial network in the 2 cell types being mainly 
fragmented in A549.B2 and fused in RD.Myo cells (Figs. 4 and 5). In A549.B2 cells, the 
fragmented mitochondrial network is enhanced by the m3243G mutant load (Fig. 4F and G), 
in parallel the mitochondrial depolarization (Fig. 6) and mitophagy (Figs. 2 and 3) are also 
increased. In fact, loss of mitochondrial membrane potential was found in A549.B2 
heteroplasmic cybrids but not in the equivalent RD.Myo cybrids (Fig. 6). Selective mitophagy 
is predicted to clear damaged mitochondria (i.e. caused by high levels of pathological mtDNA 
mutations). In this model, fission events produce 2 functionally dissimilar mitochondria: one 
with high Δψm and the other with reduced/lost Δψm. The depolarized mitochondria activate 
the PINK1-PARK2 system for the autophagy-dependent removal and destruction.4 It is well 
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known that asymmetrical fission results in uneven distribution of dysfunctional 
mitochondrial components that are expected to increase with the progressive accumulation of 
mutant mtDNA.4, 5 Hence the increase of mtQC in response to higher percentage of m3243G 
mutated mtDNA in A549.B2 cells. In heteroplasmic RD.Myo cells this response is abolished, 
leading to a progressive accumulation of m3243G-mutant mitochondria. However WT 
RD.Myo cells had high protein levels of mtPINK1 (Fig. 3A,I), absence of the mtPARK2 signal at 
around 50 kDa (Fig. 3L), and a reduced mitophagic flux. These data are difficult to explain, 
even if it is not to exclude the presence of specific protein isoforms59 and/or post-
transcriptional modifications.60 There is evidence of a PINK1 role in maintaining 
mitochondrial integrity in mild oxidative stress.61 Therefore, we can speculate that the 
increased levels of mtPINK1 in WT RD.Myo cells may be related to additional protective 
functions, which PINK1 carries out in the mitochondrial network. 
 It is still unclear why RD.Myo cells are unable to sustain selective form of autophagy 
even in face of an enhanced general autophagy. One potential explanation is the fact that 
RD.Myo cells privilege an elongated mitochondrial network for energy purpose, therefore 
blocking mitophagy (Figs. 1; 4F and G).  
 Controversial data concerning the modulation of mtDNA heteroplasmy by mitophagy 
are present in literature. Suen and Dai demonstrate that genetic62 or pharmacological63 
stimulation induces mitophagy and the progressive removal of pathogenetic mtDNA 
mutations in heteroplasmic cybrids. Hamalainen et al. describe a tissue-specific PINK1-
PARK2-mediated positive mitophagy related to MELAS pathogenesis in neuronal cells.64 
Recently Valenci has provided in vivo evidence for the PARK2-mediated change of mtDNA 
heteroplasmy.65 However, other reports fail to find specific PARK2-mediated mitophagy in 
cells with genetically- and/or chemically-induced mitochondrial depolarization.66, 67 These 
discordances may be explained by considering that interaction of the mitochondrial mutation 
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pattern with mtQC-mitophagy is a complex process dependent on multiple factors, such as 
cell bioenergetics, culture conditions, level of PARK2 expression, cell-type and specific mtDNA 
mutations.68 Noteworthy, our data were obtained in cells containing the same mutation, that 
were grown in identical culture conditions therefore minimizing the factors that strongly 
influence bioenergetic status, morphology and dynamics of mitochondria.28, 69 Therefore, the 
differences observed in mtQC and bioenergetics are due to the respective cell-type specificity.  
 A549.B2 cells had reduced glycolysis and mitochondrial mass (Fig. 1) compared to 
RD.Myo cells. Moreover the A549.B2 cells relied prevalently on OXPHOS activity for their 
energy purposes.30-32, 70 Therefore, it would be expected a preferential selection of fully 
functional mitochondria by an active mtQC process. RD.Myo cells display a greater 
bioenergetic capacity30, 32 than A549.B2 cells. Consistently, our data show higher glycolysis, 
mitochondrial mass and ATP amount (Fig.1). RD.Myo mitochondrial network appears as long 
filaments (Fig 4F and G).  A highly fused mitochondrial network is important for proper 
mitochondrial calcium buffering and for the optimal production of ATP because of a higher 
cristae density and an ideal organization of electron transfer chain components in super 
complexes.51, 71 In summary, mitochondrial fusion is advantageous under conditions of high 
energy demand, and optimizes mitochondrial function in stress conditions.71  
 Moreover, elongated mitochondria are protected from mitophagy, as recently shown in 
hearts lacking the fission protein DNM1L.72 Importantly, mitochondrial fusion allows the 
transfer of soluble and membranous components, favoring functional complementation that 
reduces the deleterious effects of mtDNA mutations to preserve respiratory function.73, 74 In 
this way, the entire mitochondrial compartment works as a single dynamic unit to maximize 
ATP synthesis.75 In this scenario, the reduced mitophagy and elimination of mutant mtDNA 
variants, together with replicative advantage of the m3243G mutation,76 might favor mutant 
mtDNA accumulation until the WT mtDNA cannot further compensate for the effect of the 
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mutant one. Consistently, a genetically-induced fusion mimics and accelerates a similar 
physiological process.21 Another key element in modulating mitochondrial dynamics is the 
redox state. Fusion is induced by oxidized glutathione77, 78 and regulated by the redox-sensing 
protein ROMO1.79 Fusion, and the consequent sharing of antioxidant defense, is considered a 
protective response to oxidative stress, preserving mitochondrial redox balance.78, 80 Indeed, 
mitochondrial fragmentation is associated with increased mitochondrial ROS levels, 
conversely tubular morphology prevents ROS production.51, 80 A549.B2 cells, but not RD.Myo 
cells, are equipped with a robust antioxidant defenses81 that maintain redox homeostasis and 
may protect them from the oxidative stress arisen by mitochondrial fragmentation (data not 
shown).  
 We might conclude that high-energy demand, functional complementation and redox 
homeostasis dictate the mitochondrial fate, favouring mitochondrial fusion, the consequent 
maintenance of high Δ m and reduced mitophagy in RD.Myo cells. Conversely, the reduced 
bioenergetic profile and the increased antioxidant defenses favour mitochondrial fission, 
mitochondrial depolarization and the increased selective mitophagy, that should be balanced 
by a limited biogenesis, in A549.B2, considering the reduced mitochondrial mass. 
 To our knowledge this study provides the first instance of a cell-type difference in 
mtQC, driven by mitophagic activity and mitochondrial dynamics.  Whereas a cell-type 
dependent regulation of mitochondrial morphology is well documented and usually linked to 
cell-type–specific functions and physiological energy demands.82 Only 2 in vivo studies in rat 
report a gender-associated tissue difference in total autophagy, but not in mitophagy.83, 84 
 The cell lines used in this investigation are cybrids obtained from immortalized cells: 
respectively from adenocarcinoma-A54923 and from rhabdomyosarcoma.45 Although these 
cells have obvious differences from their normal counterparts and mammalian tissues in vivo, 
they do maintain varying degrees of lineage specific traits. For example, A549 cells, derived 
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from human lung carcinoma, retain characteristics of type-II alveolar epithelial cells,85 while 
rhabdomyosarcoma-derived cells retain biochemical characteristics of skeletal muscle cells,86, 
87 and functional capacity to differentiate into polynuclear myotubes.22 Moreover the A549.B2 
and RD.Myo cybrids largely mirrored the bioenergetics profile of parental tissues.33 
 In summary the present data reveal a novel relationship among genetic background 
and mtQC, they strengthen the link between cell-type specific segregation of the m3243G 




MATERIAL and METHODs 
 Cell culture.  
 Homoplasmic and heteroplasmic cybrids, from rhabdomyosarcoma (RD.Myo) and 
adenocarcinoma-A549 (A549.B2) parental lines, harboring the MELAS mutation m3243G, 
were established as previously described.21-23 We used 3 0% A549.B2 and 3 0% RD.Myo 
clones; one A549.B2 and one RD.Myo clone with 100% m3243G mtDNA; heteroplasmic 
A549.B2 clones: one with 35%, one with 70%, one with 80% m3243G mtDNA; heteroplasmic 
RD.Myo clones: one with 70% and one with 80% m3243G mtDNA. Cells were grown in 
Dulbecco modified Eagle medium (4500 mg glucose/l, 110 mg pyruvate/l) (Gibco-
ThermoFisher Scientific, 41966-029), supplemented with 10% fetal bovine serum (FBS; 
Gibco-ThermoFisher Scientific, 10270-106), amino acids (Gibco-ThermoFisher Scientific, 
11130-036), L-glutamine (Sigma-Aldrich, G5763), vitamins (Biochrom, K0373), amphotericin 
B (Bristol Myers-Squibb, 6116) and antibiotics (Biochrom, A2213). For the different 
treatments, cells were seeded at a density of 1x104 cells/cm2. After 48 h the standard medium 
was supplemented with 50 µM chloroquine (Sigma-Aldrich, C6628) and the cells were 
collected 6 h later. The growth rate was evaluated as duplication time as described.88 
 Mitochondria isolation.  
 For mitochondria isolation, cells were seeded in 10 -mm) at the density 
previously reported and treated with or without 50 µM CQ. After 6 h cells were collected and 
mitochondria were isolated as described.89 Briefly, cells were scraped on ice, pelleted at 600 g 
for 5 min and washed twice in cold PBS (Gibco-ThermoFisher Scientific, 14190). The cell 
pellets were broken by adding one volume of hypotonic homogenization buffer (IB 0.1X: 3.5 
mM Tris-HCl, pH 7.8, 2.5 mM NaCl, 0.5 mM MgCl2), and homogenized by 10 or 20 strokes for 
RD.Myo or A549.B2 cybrids respectively, using a Velp Scientifica homogenizer (Italy). Soon 
after 1/10 of the packed cell volume of hypertonic buffer IB 10X was added. This homogenate 
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was centrifuged at 1200 g for 3 min at 4°C twice. The supernatant was centrifuged at 15000 g 
for 2 min at 4°C. The pellets containing the mitochondria were washed using homogenization 
buffer A (0.32 M sucrose (Sigma-Aldrich, S9378), 1 mM EDTA, and 10 mM Tris–HCl, pH 7.4) 
and the pellets were stored at -80°C until use. CS was quantified. 1000, 2000 or 5000 
nm/min/mg prot of CS activities were loaded for the different analysis. Mitochondrial 
enrichment was tested by western blot (WB) as the ratio between GADPH (cytosolic marker) 
and TOMM20 (mitochondrial marker) in the total lysate (TL) and isolated mitochondria from 
A549.B2 and RD.Myo cells.89 As shown in Fig. S8, in total lysate the ratio was 1.45 ± 0.24 
whereas in isolated mitochondria 0.08 ± 0.02. This procedure yielded 18-fold enrichment of 
mitochondrial fraction compare to total homogenate, indicating a good purification of 
mitochondria (Fig. S8). 
 Preparation of detergent-soluble and -insoluble fractions.   
 Twenty-four h after GFP-LC3B transfection, 0 and 80% A549-B2 cells were treated as 
described.90 Briefly, cells were scraped on ice and dissolved in ice-cold lysis buffer (150 mM 
NaCl, 20 mM Tris-HCl, pH 7.4, 0,5% Triton X-100 (Sigma-Aldrich, T9284), protease inhibitor 
cocktail (Sigma-Aldrich, P8340)); then were centrifuged at 500 g for 10 min at 4°C to separate 
supernatants (fractions soluble in 0.5 Triton X-100) and pellets. Pellets were resuspended in 
1% SDS in PBS Triton X-100 as insoluble fractions. The fractions were analyzed by WB.  
 Molecular analysis 
 Quantitative Real Time PCR (RT-PCR). Total RNA was isolated from cybrids using 
TRIzol Reagent (Life Technologies-ThermoFisher Scientific, 15596026). First-Strand cDNA 
synthesis was performed using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems-ThermoFisher Scientific, 43688814) and transcript levels were quantified with 
SYBR Green Real-Time PCR (Life Technologies-ThermoFisher Scientific, 11733-046) using the 
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ABI PRISM 7000 sequence detection system (Applied Biosystem-ThermoFisher Scientific, 
Foster City, CA, USA).  
 List of primer sequences: Β2M: F 5’-ATGAGTATGCCTGCCGTGTGA-3’, R 5’-
GGCATCTTCAAACCTCCA-3’, BNIP3: F 5’- GCATGAGTCTGGACGGAGTA-3’, R 5’- 
GTTTCAGAAGCCCTGTTGGT-3’; PARK2: F 5’-AAAGGCCCCTGTCAAAGAGT-3’, R 5’-
ATCATCCCAGCAAGATGGAC-3’; PINK1: F 5’- CCAAGTTTGTTGTGACCGGC-3’, R 5’- 
CTTCATAACGAGGAACAGCGTCC-3’; RPLP0: F 5’-GTGATGTGCAGCTGATCAAGACT-3’, R 5’-
GATGACCAGCCCAAAGGAGA-3’. 
 Down regulation of PINK1 and PARK2. siRNA targeting PINK1 or PARK2 were 
purchased from Sigma Aldrich 000010; 000070, scramble (GTCTCCACGCGCAGTACCATTT). 
Cybrids from adenocarcinoma or rhabdomyosarcoma were plated in 6-well plates and 
transfected with 75 pmol of each siRNA oligo using Lipofectamine 2000 (Life Technologies-
ThermoFisher Scientific, 11668-027). At 24 h or 48 h post-transfection, cells were collected 
and lysed as described in the ‘Biochemical analysis’ section.  
 mtDNA removal. WT or heteroplasmic A549.B2 and RD.Myo cybrids were treated with 
or without 50 ng/ml EtBr (Sigma-Aldrich, E8751) and with or without 50 µM CQ. After 22 h, 
cells were collected and the DNA was extracted, as described previously.21 In each sample the 
mtDNA copy number was quantified by SYBR Green (Life Technologies-ThermoFisher 
Scientific, 11733-046), quantitative Real Time PCR, using the ABI PRISM 7000 sequence 
detection system (Applied Biosystem-ThermoFisher Scientific, Foster City, CA, USA). The 
mtDNA copy number was related to the AR (androgen receptor) gene. The following primers 
were used: AR: F 5’-CAACTCCTTCAGCAACAGCA-3’, R 5’-GGACACCGACACTGCCTTAC-3’; MT-
CO2: F 5′-CGTCTGAACTATCCTGCCCG-3′, R 5′-TGGTAAGGGAGGGATCGTTG-3’. 
 Mitochondrial genotyping by last-cycle-hot PCR. The amount of heteroplasmy for the 
m3243G mutation was measured in DNA samples extracted from cells as described 
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previously.21 Briefly, the regions around the mutation site in the MT-TL1 gene, were PCR 
amplified using mtDNA-specific primer pairs: F 5´- GTTCGTTTGTTCAACGATT -3´; R 5´- 
GGTAAGATTACCGTTACCG -3´, with addition of [α-33P]dCTP (Hartmann Analytic, 
SRF205/09.25) in the last synthesis cycle. Labeled PCR products were then digested with the 
restriction enzyme, diagnostic for the site polymorphisms created by the mutations (ApaI) 
(New England Biolabs, R0114S), and products of replicate digestions were separated by 
polyacrylamide gel electrophoresis and phosphoimages were analyzed with Gel-Pro Analyzer 
software. 
 Biochemical analysis 
 Western blotting analysis. Total cell lysates were prepared by maintaining the cells on 
ice for 30 min with 200 μl of RIPA buffer (65 mM Tris, 150 mM NaCl, 1% Nonidet P-
40/IGEPAL CA-630 (Sigma-Aldrich, I3021), 0.25% Na-DOC (Sigma-Aldrich, D6750), 1 mM 
EDTA, pH 7.4) and 7 l of a cocktail of protease inhibitors (Sigma-Aldrich, P8340)). 
Mitochondria were extracted as described previously.89 Total protein levels were determined 
using the BCA protein assay kit (ThermoFisher Scientific, 23227). After centrifugation at 
14,000 gmax for 15 min at 4°C, an equal amount of protein (30 µg) for each sample was 
separated by SDS-PAGE (12% acrylamide) and transferred to nitrocellulose membrane. The 
membrane was blocked in 5% (w/v) fat-free milk in 0.02 M Tris-HCl, pH 7.5, 137 mM NaCl, 
and 0.1% (v/v) Tween 20 (Sigma-Aldrich, P1379) for 1 h at room temperature. The 
membrane was incubated overnight at 4°C in primary antibodies to: anti-LC3B monoclonal 
(Sigma-Aldrich, L7543; 1:2000); anti-SQSTM1 monoclonal (Sigma-Aldrich, 041M4812; 
1:5000); anti-PINK1 monoclonal (Cell Signaling Technology, D8G3; 1:1000); anti-PARK2 
monoclonal (Santa Cruz Biotechnology, sc-32282; 1:500); anti-BNIP3 polyclonal (Sigma-
Aldrich, B7931; 1:1000), anti-DNM1L monoclonal (BD Biosciences, 611112; 1:1000); anti-p-
DNM1L S637 polyclonal (Cell Signaling Technology, 4867S; 1:1000); anti-MFN1 monoclonal 
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(Merck-Millipore, ABC41; 1:1000); anti-MFN2 monoclonal (Abnova, H00009927-M03; 
1:1000); anti-OPA1 monoclonal (BD Biosciences, 612606; 1:1000); anti-FUNDC1 polyclonal 
(Santa Cruz Biotechnology, sc-133597; 1:1000); anti-BCL2L13 monoclonal (Santa Cruz 
Biotechnology, sc-390598; 1:1000); anti-ACTB monoclonal (Chemicon International-
Millipore, MAB1501; 1:4000); anti-TOMM20 polyclonal (Santa Cruz Biotechnology, sc-11415; 
1:1000); anti-ATP5J/ATP5A monoclonal (Abcam, ab110273; 1:10000); anti-GAPDH 
monoclonal (Mark-Millipore, MAB374; 1:5000); anti-ubiquitin monoclonal (Mark-Millipore, 
MAB1510; 1:1000). Bound secondary peroxidase conjugated antibodies: anti-mouse (GE 
Healthcare, NA931B); anti-rabbit (GE Healthcare, NA934B) were visualized using an ECL 
reagent (GE Healthcare, RPN2106). Densitometric analysis of WB signal was performed using 
Gel-Pro Analyzer 3 software. 
 Citrate synthase activity was assayed by incubating cell samples with 0.02% Triton X-
100, and monitoring the reaction by measuring the rate of free coenzyme A release 
spectrophotometrically according to Sgarbi et al.91 
 Mitochondrial membrane potential. Mitochondrial membrane potential (Δψm) changes 
were evaluated by measuring rhodamine 123 fluorescence quenching91, 92 under the following 
conditions: 2 x 106 cells were added to 0.5 ml buffer (250 mM sucrose, 10 mM HEPES, 100 AM 
K-EGTA, 2 mM MgCl2, 4 mM KH2PO4, pH 7.4) containing an ADP regenerating system (10 mM 
glucose and 2.5 U Hexokinase (Sigma-Aldrich, H5000)) and permeabilized with 20 µg/ml of 
digitonin (Sigma-Aldrich, D5628). Before rhodamine 123 (Molecular Probes ThermoFisher 
Scientific, R302) (50 nM) addition, samples were incubated with 1.8 mM malonate (Sigma-
Aldrich, M4795), and 0.1 mM ADP (Sigma-Aldrich, A6646). Finally, mitochondria were 
energized by 10 mM:10 mM glutamate (Sigma-Aldrich, G1251):malate (Sigma-Aldrich, 7554-
12-3) in the presence or absence of oligomycin (Sigma-Aldrich, 75351) (0.2 µM) to detect 
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membrane potential changes associated with state 4 and state 3 respiratory conditions, 
respectively. 
 Mitochondrial ATP synthesis rate and cellular ATP content assay. The oligomycin-
sensitive ATP synthase activity in permeabilized cells was determined according as 
decribed.91, 92 Essentially, cybrids (2 x 106 cells/ml) were incubated for 15 min with 60 mg/ml 
digitonin in a Tris-HCl buffer, pH 7.4. Complex I-driven ATP synthesis was induced by adding 
10 mM:10 mM glutamate:malate (+ 0.6 mM malonate (Sigma-Aldrich, M4795)) and 0.5 mM 
ADP (Sigma-Aldrich, A6646) to the sample. 2 to 3 min later the reaction was stopped by 
adding dimethylsulphoxide (Sigma-Aldrich, D4540). Newly synthesized ATP and intracellular 
ATP were measured by bioluminescence using a luciferin–luciferase system (ATP 
bioluminescent assay kit CLS II; Roche, 11699695001) according to the manufacturer's 
instructions. The amount of ATP measured was referred to sample cell number. 
 Flow cytometry analysis.  
 Mitochondrial depolarization was evaluated by following the loss of TMRM 
(tetramethylrhodamine methyl ester; Molecular Probes Thermofisher Scientific, T668) 
staining in a nonquenching mode,58 by using FACS analyser (FACS Canto Analyser, Becton-
Dickinson, Franklin Lakes, NJ, USA), as described.93 Cells were preincubated with 20 nM 
TMRM and 1.6 µM cyclosporine H (Enzo Life Sciences, ALX-380-286), to inhibit the 
nonspecific cell extrusion of the probe by P-glycoprotein, for 30 min. Cells were washed with 
PBS, trypsinized, centrifuged and resuspended in 300 µl of PBS. After first acquisition at t = 0, 
1.6 µM oligomycin was added and loss of TMRM fluorescence was monitored over time at t = 





 Imaging.  
 A549.B2 and RD.Myo cybrids harboring 0%, 70% and 80% m3243G mutant mtDNA 
were: i) transiently transfected with mtRFP94 and GFP-LC3B95 using Lipofectamine 2000. 24 h 
after transfection, the cells were fixed in 4% formaldehyde (Carlo Erba Reagents, 415661) 
and observed with a confocal microscope (LEICA TCS SP5, Wetzlar, Germany); ii) 
untransfected and analyze with anti-LC3B and anti-ATP5J/ATP5A antibodies. For 
immunohistochemical analysis, the cells were fixed in 4% formaldehyde, treated with 0.5% 
Triton X-100 for 5 min and with blocking solution (10% FBS in PBS) for 30 min, then were 
sequentially incubated at 4°C in separate overnight sections with primary polyclonal anti-
LC3B (Cell Signaling Technology, 2775; 1:200) and monoclonal ATP5J/ATP5A (Abcam, 
ab110273, 1:200) in 10% FBS+PBS. The appropriate secondary fluorescent antibody (Alexa 
Fluor 488 (Invitrogen ThermoFisher Scientific, A11008) for anti-LC3 and Alexa Fluor 647, 
(Invitrogen ThermoFisher Scientific, A21235) for anti-ATP5J/ATP5A) was used for 1 h at 
room temperature at the end of the respective section. In the z-axis stacks acquired, each 
image was separated by 0.5 µm along the z-axis. Using the Fiji program, the number of objects, 
in voxel, was analyzed in each green and red slide of the Z-stack. The autophagosome is a 
globular organelle with a diameter of approximately 1 µm. Only the voxels with that 
dimension or greater were considered.96 Colocalization: once obtained all the voxels with the 
right dimension, the colocalization was analyzed using the following formula: 
 √(𝑥1 − 𝑥2)2 + (𝑦1 − 𝑦2)2 + (𝑧1 − 𝑧2)2 . A red-green colocalized voxel was considered only 






 Statistical analysis.  
 Data were expressed as mean ± SD or mean ± SE. Statistical analysis of group 
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LEGEND TO THE FIGURES 
Figure 1. Bioenergetic parameters in A549.B2 and RD.Myo cells with different m3243G 
mutant mtDNA. (A) Mitochondrial ATP synthesis rate fuelled by glutamate-malate in 
permeabilized A549.B2 and RD.Myo cells. Values normalized for CS (citrate synthase) activity, 
expressed as mean ± SD. (B) Mitochondrial mass express as CS activity. Values, normalized for 
number of cells, expressed as mean ± SD. (C) ATP level in total cellular lysate from A549.B2 
and RD.Myo cells. Values, normalized for number of cells, expressed as mean ± SD. (D and F) 
HK2 protein level in total lysate and (E and G) in isolated mitochondria from A549.B2 and 
RD.Myo cells. In F HK2 blots at low (3 sec) and high (10 sec) exposure to visualize HK2 in 
A549.B2 cells. Values, normalized for ACTB (actin beta) (total lysate) and TOMM20 
(translocase of outer mitochondrial membrane 20) (isolated mitochondria), expressed in a.u., 
(arbitrary units)  as mean ± SD. (H and I) Mitochondrial membrane potential  in A549.B2 (H) 
and RD.Myo (I) cells in the presence of ADP (state 3) and in the absence of ADP (state 4), 
expressed as mean ± SD of fluorescent quencing (F.Q). All the data are obtained from 3 
different experiments. Significance by the Student t test: *, P < 0.05; **, P< 0.01; ***, P< 0.001.  
 
Figure 2. LC3-II and SQSTM1/p62 protein levels in total lysate and in isolated mitochondria 
of A549.B2 and RD.Myo cells with increased m3243G mutant mtDNA. LC3-II (A) and 
SQSTM1/p62 (B) were tested by WB analysis in total cellular lysate of A549.B2 (C) and 
RD.Myo (D) cells. In isolated mitochondria of the same cells mtLC3-II (E), and 
mtSQSTM1/p62 (F) tested by WB analysis (G). In mtLC3 blot (G) at low exposure (5 sec) only 
LC3-II band was present; an high exposure (60 sec) visualized both the LC3-I and LC3-II 
bands. Autophagic flux, expressed as ratio +/- chloroquine (CQ) (50 μM) untreated and 
treated cells for 6 h. Values, normalized for ACTB (total lysate) and TOMM20 (isolated 
mitochondria), expressed as mean ± SE. Data are representative of 3 or more independent 
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experiments. In A549.B2 correlation between percentage of mutant load and level of mtLC3-II 
(H), mtSQSTM1/p62 (M); in RD.Myo correlation between mutant load and level of mtLC3-II 
(L), mtSQSTM1/p62 (N). Significance by the Student t test: *, P < 0.05; **, P< 0.01; ***, P< 
0.001. a.u., arbitrary units. 
 
Figure 3. PINK, PARK2 and BNIP3 protein levels in isolated mitocondria of A549.B2 and 
RD.Myo cells with increased m3243G mutant mtDNA. mtPINK (A and I), mtPARK2 (B and L), 
and mtBNP3 (C and M) were tested by WB analysis. Mitophagic flux, expressed as ratio +/- 
between CQ (50 µM) untreated and treated cells for 6 h. Values, normalized for TOMM20, 
expressed as mean ± SE. In A549.B2 correlation between mutant load and level of mtPINK1 
(D), of mtPARK2 (F), of mtBNIP3 (G). In RD.Myo correlation between mutation and level of 
mtPINK1 (E), of mtBNIP3 (H). Gene expression profiles of housekeeping genes RPLP0 and 
B2M (N); of PINK1 (O); of PARK2 (P) and of BNIP3 (Q) in A549.B2 and RD.Myo cells, 
quantified by RT-PCR. Data expressed as mean ± SE. In (N) the RNA level of RPLP0 and B2M 
was quantified in 107 cells. Data are obtained from 3 or more independent experiments.  
Significance by the Student t test: *, P < 0.05; **, P< 0.01; ***, P< 0.001. a.u., arbitrary units. 
 
Figure 4. MtDNA removal, mitophagy and mitochondrial morphology in A549.B2 and RD.Myo 
cells with increased m3243G mutant mtDNA. mtDNA copy number in 0% and heteroplasmic 
mutant A549.B2 (A) and RD.Myo (B) cells treated for 22 h with ethidum bromide (EtBr) in the 
presence or absence of CQ. The ratio of mtDNA values between +/- CQ (50 µM) treated and 
untreated cells represented the mitophagic mtDNA removal. Data obtained from 3 
independent experiments. Representative images of A549.B2 (C) and RD.Myo (D) cells with 
0%, 70% and 80% mutant mtDNA transfected with GFP-LC3B (green) and mtRFP (red) target 
to mitochondria in the absence or presence of 50 µM CQ. Zoom: magnification of white insert 
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area. Scale bar: 10 μm. (E) Quantification of mitophagy as LC3-mitochondrial colocalization 
(yellow), express as mean ± SE of puncta : cell scored in over 50 cells from multiple field for 
each category. (F) Representative images of mitochondrial network in A549.B2 and RD.Myo 
cells, untreated with CQ. Mitochondria visualized in cells transfected with mtRFP and 
analyzed at confocal microscopy. Scale bar: 10 μm. (G) Percentage of cell population with 
fragmented, medium and elongated mitochondria in A549.B2 with 35%, 70% and 80% 
mutant mtDNA and in RD.Myo cells with 0%, 70% and 80% mutant mtDNA. Over 100 cells 
were scored for each category. Values expressed as the mean ± SD. Significance by the Student 
t test : *, P < 0.05; **, P< 0.01; ***, P< 0.001. a.u., arbitrary units. 
 
Figure 5. DNM1L, MFN1, MFN2, and OPA1 protein levels in isolated mitochondria of A549.B2 
and RD.Myo cells with increased m3243G mutant mtDNA. Mitochondrial DNM1L  (A, C),  
MFN1 (E); MFN2 (F), and OPA1 (G) tested by WB analysis (H). Values from isolated 
mitochondria of cells untreated with CQ, normalized to TOMM20 and expressed as the mean ± 
SE.  Ratio of phospho DNM1L:total cytosolic DNM1L  in total cell lysate (B, D), expressed as 
the mean ± SE. Data are obtained from 3 or more independent experiments. Significance by 
the Student t test : *, P < 0.05; **, P< 0.01; ***, P< 0.001. a.u., arbitrary units. 
 
Figure 6. Mitochondrial depolarization in response to oligomycin in A549.B2 and RD.Myo 
cells with increased m3243G mutant mtDNA. Cells were loaded with TMRM (20 nM) for 30 
min at 37°C and were analyzed by flow cytometry after 90 min of oligomycin (1.6 µM) 
treatment. Percentage of depolarization of A549.B2 (A) and RD.Myo (B) cybrids. Total 
depolarization of all the cells by addition of the protonophore FCCP (5 µM). (C) Positive 
correlation between mutant load and depolarized cells in A549.B2 but not in RD.Myo cells. 
(D) Positive correlation between mutant load and ratio +/- CQ of percentage of depolarization 
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in A549.B2 but not in RD.Myo. Values expressed as the mean ± SD. Data obtained from 3 
independent experiments. Significance by the Student t test: *, P < 0.05; **, P< 0.01; ***, P< 
0.001.  
 
Figure S1. Mutant mtDNA load and growth rate in A549.B2 and RD.Myo cells. (A and B) DNA 
was harvested at intervals over a period of 12 to 96 months and the proportion of mutant 
mtDNA estimated by last-cycle hot-PCR (see Materials and Methods). During the current 
study the average level of mutant mtDNA varied from 70 to 73% in 70% mutant A549.B2 cells 
and from 78 to 82% in 80% mutant A549.B2 cells;  from 78 to 79% and from 88 to 89% in 
70% and 80% mutant RD.Myo cells respectively. (C) Growth rate of WT and heteroplasmic 
A549.B2 and RD.Myo cells expressed as duplication time in hours, as described in the 
Materials and Methods section. 
 
Figure S2. PINK1, PARK2, BNIP3, LC3-II, and SQSTM1/p62 protein amount in isolated 
mitochondria from A549.B2 and RD.Myo cells. Representative WB analysis of the indicated 
proteins in isolated mitochondria from A549.B2 (A) and RD.Myo (B) cells in the presence or 
absence of CQ. mtLC3 blot  was at low exposure and  visualized  only LC3-II band, as shown in 
Fig 2G. Data are representative of 3 or more independent experiments. 
 
Figure S3. Positive correlation between percentage of mutation and autophagic flux of 
mitophagic proteins from isolated mitochondria of A549.B2. Mitophagic flux of mtLC3-II (A), 
mtSQSTM1/p62 (B), mtPINK1 (C), mtPARK2 (D), mtBNIP3 (E), in A549.B2 isolated 
mitochondria positively correlates with mutant load. Autophagic flux is expressed as ratio of 
the values obtained in the presence and in the absence of CQ. The correlation is visualized as 
straight line and formula.   
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Figure S4. Knockdown of PINK1 and PARK2 protein level in A549.B2 and RD.Myo cybrids 
after PINK1 and PARK2 siRNA transfection. PINK1 (A and C) and PARK2 (B and D) protein 
levels were tested by WB analysis in total lysate of 80% mutant A549.B2 and 0% RD.Myo 
cells, transfected for 24 h with scramble or with vectors producing shRNAs specific for PINK1 
and PARK2. Total cellular lysates and isolated mitochondria (mito)(used as internal marker) 
were immunoblotted together and probed for PINK1, PARK2, ACTB and ATP5J (ATP synthase, 
H+ transporting, mitochondrial Fo complex subunit F6). (C) siRNA determined a reduction of 
PINK1 protein level, normalized for ACTB, at 21% and 47% in A549.B2 and RD.Myo, 
respectively. (D) Similarly the protein amount of PARK2 was reduced at 35% in A549.B2, 
whereas PARK2 bands at around 50 kDa were not detected in RD.Myo cells. The experiment 
confirmed the presence of PINK1 variants with differences in molecular mass in A549.B2 vs 
RD.Myo cells. PINK1 (C) and PARK2 (D) protein amount, expressed as percentage of the value 
in cells treated with scramble siRNA (100%). Data are representative of 3 independent 
experiments, expressed as mean ± SE. a.u., arbitrary units.  
 
 Figure S5. BCL2L13 and FUNDC1 protein levels in isolated mitochondria of A549.B2 cells 
with increased m3243G mutant mtDNA. (A) Isolated mitochondria of A549.B2 cells, treated 
with or without CQ, were immunoblotted against BCL2L13, FUNDC1 and ATP5J as protein 
load. (B and C) Values, normalized for ATP5J, expressed as mean ± SE . Significance by the 
Student t test: *, P < 0.05; **, P< 0.01; ***, P< 0.001. Data are representative of 2 independent 
experiments. a.u., arbitrary units.  
 
Figure S6. Quantification of mitophagy as endogenous LC3-mitochondrial colocalization in 
A549.B2 and RD.Myo cells and absence of GFP-LC3 aggregates. (A) Representative images of 
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A549.B2 and RD.Myo cells, with 0% and with 80% mutant mtDNA, immunostained with anti-
LC3B (green) and anti-ATP5J (red) in the presence of 50 µM CQ. (B) Quantification of 
mitophagy as endogenous LC3-mitochondrial colocalization (yellow), expressed as mean ± SE 
of puncta: cell scored in over 50 cells from multiple fields for each category. The colocalization 
analysis of endogenous LC3 confirmed the higher mitophagic flux present in A549.B2 and not 
in RD.Myo. Scale bar: 5 μm. (C) Detergent-soluble (Supernatant) and -insoluble (Pellet) 
fractions of GFP-LC3B, transfected in 0% and 80% A549.B2 cells, were immmunoblotted 
against ubiquitin, LC3B and ACTB, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as 
loading control, as described in the Materials and Method section. GFP-LC3B was present in 
the soluble fraction, together with GAPDH and ACTB, whereas, as expected, ubiquitinated 
protein aggregates were observed in the insoluble-pellet fraction. Significance by the Student 
t test: *** P< 0.001. Data are representative of 2 independent experiments.  
 
Figure S7. Mitochondrial depolarization in response to oligomycin in A549.B2 and RD.Myo 
cells with increased m3243G mutant mtDNA. (A) Mitochondrial depolarization, expressed as 
percentage of TMRM-negative cells in A549.B2 and RD.Myo cells, in the absence (Basal) and in 
the presence of CQ and of the protonophore FCCP. (B) Representative flow cytometry dot 
plots of A549.B2 and RD.Myo cells. (C) Positive correlation between mutant load and 
depolarized cells was present in CQ-treated A549.B2 but not in RD.Myo cells. Significance by 
the Student t test: *, P < 0.05; **, P< 0.01; ***, P< 0.001. Data are representative of at least 3 
independent experiments.  
 
Figure S8. Purity of mitochondrial enrichment. (A) Mitochondrial enrichment evaluated as 
ratio of cytosolic GAPDH and mitochondrial TOMM20 markers in total lysate (TL) and 
mitochondrial fraction from A549.B2 and RD.Myo cells by WB analysis.89 (B) Representative 
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WB of total lysate and mitochondrial fractions, expressed as CS activity, blotted against 
GAPDH and TOMM20. Data are representative of 3 independent experiments. a.u., arbitrary 
units.  
 
